S
SCYX
Scynexis
0.8940
+0.0061+0.69%Opening14:14 04/06 EDT
OPEN/PREV CLOSE0.9700/0.9960
TODAY RANGE0.9503-0.9986
VOL582
MARKET CAP44.31M
52 WEEK RANGE0.5650-1.310
AVG VOL (3M)596.77K
% TURNOVER0.81%
TURNOVER0
P/E (TTM)-5.7541
% RANGE4.85%
EPS(TTM)-0.1724
P/E(FORWARD)-1.8036
P/B0.8748
BVPS1.134
DIVIDEND--
P/S2.097
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP42.65M
SHARES OUTSTANDING44.66M
NEXT EARNINGS05/13-05/18
FREE FLOAT43.00M
LOT SIZE1
EX-DATE07/17/2020
News
Press Releases
Financial Reports
Profile
Reuters·04/02 12:02
SCYNEXIS CEO David Angulo Gonzalez buys common shares for $0.1 million
Seeking Alpha·04/01 14:04
ISM Manufacturing unexpectedly rises in March
TipRanks·03/31 23:54
SCYNEXIS Acquires SCY-770, Refocuses on Rare Kidney Disease
Reuters·03/31 21:29
SCYNEXIS completes acquisition of Poxel’s PXL-770 for ADPKD treatment
Reuters·03/31 21:06
Poxel sells PXL770 to Scynexis for up to $200 million
TipRanks·03/31 14:49
SCYNEXIS Acquires AMPK Program, Expands Rare Disease Pipeline
TipRanks·03/31 14:46
SCYNEXIS Raises $40 Million in Strategic Private Placement
NASDAQ·03/31 11:42
Poxel To Sell PXL770 To Scynexis For Up To $196 Mln; Shares Up
TipRanks·03/31 11:20
Poxel announces sale of PXL770 to Scynexis for up to $196M
Benzinga·03/31 10:51
SCYNEXIS Announces $40M Private Placement, Warrants May Add $52M To Proceeds
TipRanks·03/31 10:50
Scynexis completes acquisition of PXL-770 for treatment of kidney disease
TipRanks·03/31 10:50
Scynexis announces $40M private placement
Reuters·03/31 10:45
SCYNEXIS ANNOUNCES $40.0 MILLION PRIVATE PLACEMENT
Reuters·03/31 10:45
SCYNEXIS INC - ESTIMATES FUNDS WILL SUPPORT OPERATIONS INTO MID-2029
Dow Jones·03/31 10:45
Press Release: SCYNEXIS Announces $40.0 Million Private Placement
Same Industry
Name/Symbol
Change%
Price
Contact Us
Contact Number :+852 3852 8500Monday 7:00 AM - Saturday 9:00 AM (HKT)
Service Email :service@webull.hkOnline Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)
Business Cooperation :marketinghk@webull.hkRisk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2026 Webull Securities Limited. All rights reserved.